Executive readout · one minute
What the filings say
- 8-K earnings release · filed Nov 5, 2026
- Cogent Biosciences reported a $111.4 million 2026 third-quarter net loss and $791.1 million cash. Bezuclastinib FDA decision dates are November 30, 2026 for GIST, December 30, 2026 for NonAdvSM and June 29, 2027 for AdvSM.
- 10-Q report · filed Nov 5, 2026
- Cogent has three bezuclastinib NDAs pending FDA review, with PDUFA target dates November 30, 2026, December 30, 2026 and June 29, 2027. Cash, cash equivalents and marketable securities of $791.1 million were expected to fund operations into late 2028.
The audio replay and transcript follow the call.